

## HR 1730

Speeding Therapy Access Today Act of 2021

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 10, 2021

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 10, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/1730>

### Sponsor

---

**Name:** Rep. Bilirakis, Gus M. [R-FL-12]

**Party:** Republican • **State:** FL • **Chamber:** House

**Cosponsors** (40 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Butterfield, G. K. [D-NC-1]	D · NC		Mar 10, 2021
Rep. Soto, Darren [D-FL-9]	D · FL		Mar 16, 2021
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Mar 23, 2021
Rep. Van Drew, Jefferson [R-NJ-2]	R · NJ		Apr 5, 2021
Rep. Levin, Mike [D-CA-49]	D · CA		Apr 19, 2021
Rep. Joyce, John [R-PA-13]	R · PA		Apr 26, 2021
Rep. Davis, Rodney [R-IL-13]	R · IL		May 11, 2021
Rep. Tenney, Claudia [R-NY-22]	R · NY		May 11, 2021
Rep. Lee, Susie [D-NV-3]	D · NV		May 12, 2021
Rep. Wild, Susan [D-PA-7]	D · PA		May 14, 2021
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		May 17, 2021
Rep. Delgado, Antonio [D-NY-19]	D · NY		May 18, 2021
Rep. Lesko, Debbie [R-AZ-8]	R · AZ		Jun 1, 2021
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Jun 1, 2021
Rep. Jacobs, Chris [R-NY-27]	R · NY		Jun 11, 2021
Rep. Cole, Tom [R-OK-4]	R · OK		Jun 15, 2021
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Jul 22, 2021
Rep. Kelly, Mike [R-PA-16]	R · PA		Jul 22, 2021
Rep. Ross, Deborah K. [D-NC-2]	D · NC		Jul 22, 2021
Rep. Gottheimer, Josh [D-NJ-5]	D · NJ		Aug 3, 2021
Rep. Kustoff, David [R-TN-8]	R · TN		Aug 3, 2021
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		Oct 15, 2021
Rep. Huffman, Jared [D-CA-2]	D · CA		Oct 15, 2021
Rep. Lynch, Stephen F. [D-MA-8]	D · MA		Oct 21, 2021
Rep. Phillips, Dean [D-MN-3]	D · MN		Dec 23, 2021
Rep. Neguse, Joe [D-CO-2]	D · CO		Feb 8, 2022
Resident Commissioner González-Colón, Jenniffer [R-PR-At Large]	R · PR		Feb 25, 2022
Rep. Axne, Cynthia [D-IA-3]	D · IA		Mar 9, 2022
Rep. Bishop, Sanford D., Jr. [D-GA-2]	D · GA		Mar 9, 2022
Rep. Dean, Madeleine [D-PA-4]	D · PA		Mar 9, 2022
Rep. Swalwell, Eric [D-CA-15]	D · CA		Mar 9, 2022
Rep. Yarmuth, John A. [D-KY-3]	D · KY		Mar 9, 2022
Rep. O'Halleran, Tom [D-AZ-1]	D · AZ		Mar 11, 2022
Rep. Stansbury, Melanie Ann [D-NM-1]	D · NM		Mar 11, 2022
Rep. Crow, Jason [D-CO-6]	D · CO		Mar 15, 2022
Rep. Wilson, Joe [R-SC-2]	R · SC		Mar 15, 2022
Rep. Hill, J. French [R-AR-2]	R · AR		Mar 18, 2022
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Mar 18, 2022
Rep. Mullin, Markwayne [R-OK-2]	R · OK		Mar 31, 2022
Rep. Bacon, Don [R-NE-2]	R · NE		Apr 21, 2022

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 10, 2021

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
117 S 670	Identical bill	Mar 10, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

## Summary (as of Mar 10, 2021)

### Speeding Therapy Access Today Act of 2021

This bill requires and authorizes various actions to accelerate the development of therapies for rare diseases.

The Food and Drug Administration (FDA) shall establish the Intercenter Institute on Rare Diseases and Conditions. The institute shall (1) coordinate engagement with relevant stakeholders, (2) build the FDA's expertise in the review of medical products to treat rare diseases, (3) coordinate regulatory science initiatives related to rare diseases, (4) establish and implement a program to make recommendations to address challenges associated with developing medical products to treat rare diseases in an individual or in very small populations, (5) convene a stakeholder meeting to consider potential amendments to labels for medical products to treat rare diseases, and (6) establish and carry out a program to facilitate voluntary communication between the sponsors of such medical products and third-party payers (e.g., insurance companies).

The bill also authorizes the FDA to make grants to assist in developing practices related to the development and production of individualized therapies or therapies to treat very small populations.

The bill also establishes an advisory committee to advise the FDA on issues related to the development of therapies to treat rare diseases.

## Actions Timeline

- **Mar 10, 2021:** Introduced in House
- **Mar 10, 2021:** Referred to the House Committee on Energy and Commerce.
- **Mar 10, 2021:** Referred to the Subcommittee on Health.